Roy S. Herbst

Dr. Herbst is recognized for his leadership and expertise in lung cancer treatment and research. His work involves developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. He is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; the associate director for translational research, Yale Cancer Center; and the translational working group leader, Thoracic Oncology Program, Yale Cancer Center.

As a member of the American Association for Cancer Research (AACR), Dr. Herbst has chaired the Tobacco Task Force as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. Currently a fellow of the American College of Physicians, he has also been a vice chair of the Southwest Oncology Group’s lung committee, a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored 200+ peer-reviewed papers and has current grant funding for his work from sources including the National Cancer Institute, AACR and multiple charitable foundations.

After receiving B.S. and M.S. degrees from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital, and he completed his clinical fellowships in medicine and hematology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Most recently, he completed an M.S. degree in clinical translational research at Harvard University.